other:Article Title: 18F-FDG-PET/CT-negative gastric cancer employs glutamine-based gluconeogenesis and fatty acid oxidation to support tumor growth
Article Snippet: Primary antibodies included: anti-GLUT1 (Proteintech, #21829-1-AP), anti-HK2 (Cell Signaling Technology, #2106), anti-PFKP (Cell Signaling Technology, #5412), anti-ALDOA (Cell Signaling Technology, #3188), anti-TPI (Cell Signaling Technology, #34088), anti-GAPDH (Cell Signaling Technology, #2118), anti-PGK1 (Cell Signaling Technology, #68540), anti-ENO (Cell Signaling Technology, #3810), anti-PKM2 (Cell Signaling Technology, #3198), anti-ASCT2 (ABclonal, #A20485), anti-GLS (ABclonal, # A20554 ), anti-FH (ABclonal, #A20451), anti-MDH1 (ABclonal, #A20885), anti-MDH2 (ABclonal, #A20674), anti-PCK1 (ABclonal, #A2036), anti-PCK2 (Proteintech, #14892-1-AP), anti-FBP1 (ABclonal, #A20564), anti-CPT1A (ABclonal, #A20193), anti-ACADVL (ABclonal, #A20187), anti-ACADM (ABclonal, #A20365), anti-ACADS (ABclonal, #A20458), anti-ECHS1 (ABclonal, #A20967), anti-HADH (ABclonal, #A20879), anti-GLUT1 (Proteintech, #21829-1-AP), anti-PGC1α (ABclonal, #A20995), anti-CREB1 (ABclonal, #A11989), anti-FOXO1 (ABclonal, #A2934), anti-PPARγ (Cell Signaling Technology, #2435S) and anti-β-Actin (Proteintech, #23660-1-AP).
Article Title: 18F-FDG-PET/CT-negative gastric cancer employs glutamine-based gluconeogenesis and fatty acid oxidation to support tumor growth.
Article Snippet: Primary antibodies included: anti-GLUT1 (Proteintech, #21829-1-AP), anti-HK2 (Cell Signaling Technology, #2106), anti-PFKP (Cell Signaling Technology, #5412), anti-ALDOA (Cell Signaling Technology, #3188), anti-TPI (Cell Signaling Technology, #34088), anti-GAPDH (Cell Signaling Technology, #2118), anti-PGK1 (Cell Signaling Technology, #68540), anti-ENO (Cell Signaling Technology, #3810), anti-PKM2 (Cell Signaling Technology, #3198), anti-ASCT2 (ABclonal, #A20485), anti-GLS (ABclonal, #A20554), anti-FH (ABclonal, #A20451), anti-MDH1 (ABclonal, #A20885), anti-MDH2 (ABclonal, #A20674), anti-PCK1 (ABclonal, #A2036), anti-PCK2 (Proteintech, #14892-1-AP), anti-FBP1 (ABclonal, #A20564), anti-CPT1A (ABclonal, #A20193), anti-ACADVL (ABclonal, #A20187), anti-ACADM (ABclonal, #A20365), anti-ACADS (ABclonal, #A20458), anti-ECHS1 (ABclonal, #A20967), antiHADH (ABclonal, #A20879), anti-GLUT1 (Proteintech, #21829-1-AP), anti-PGC1α (ABclonal, AR TI CL E IN P RE SS #A20995), anti-CREB1 (ABclonal, #A11989), anti-FOXO1 (ABclonal, #A2934), anti-PPARγ (Cell Signaling Technology, #2435S) and anti-β-Actin (Proteintech, #23660-1-AP).
|